Clinical trial
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
NCT00445315 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00445315 |
|---|---|
| Title | A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients |
| Official title | A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | PF-00868554, Placebo |
| Enrollment | 32 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Mar 8, 2007 |
| Last update posted | Feb 17, 2014 |
| Countries | Belgium, Germany, United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: